Therefore, we suspected that some ceRNA triples, such as DLEU2–hsa-miR-30a-5p–CCNA2, DLEU2–hsa-miR-30a-5p–MYBL2, DLEU2–hsa-miR-30a-5p–DTL, and DLEU2–hsa-miR-30a-5p–STMN1, are potential therapeutic targets in GC. This evidence concerns the gene DLEU2 and gastric cancer.